Disclosed is a tablet comprising selonsertib (5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide) and its use as an apoptosis signal-regulating kinase inhibitor for the treatment of kidney fibrosis, liver fibrosis, lung fibrosis, diabetic nephropathy or diabetic kidney disease. Also disclosed are the two intermediates 5-(4-cyclopropy1-1H-imidazol-1-y1)-2-fluoro-4-methylbenzoic acid and 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine used in the preparation of said compound Selonsertib.
